This study aims to identify Annexin A1 as a diagnostic biomarker for cyclic Cushing’s syndrome by integrating clinical and multi-omics data, demonstrating its elevated expression in tumor and serum during the remission phase to distinguish this condition from conventional Cushing’s disease.